drugset
drugset / Trial / NCT04183764

MAX-40279-01 in Patients With Advanced Solid Tumors

NCT04183764 ↗

Phase 1 Unknown 30 enrolled Maxinovel Pty., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-40279-01 in patients with advanced solid tumor.

Timeline

Start
2019-11-28
Primary completion
2022-11-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MAX-40279-01 Unknown 5 mg —
Subject MAX-40279-01 Unknown 25 mg —

Indications

cancer